BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dalpiciclib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Dalpiciclib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04486911-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT04486911)
DESCRIPTION:Dalpiciclib\, phase 2.\nStudy: Pyrotinib Maleate\, CDK4/6 Inhib
 itor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial\
 nEstimated primary completion: 1 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04486911
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06107673-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT06107673)
DESCRIPTION:Dalpiciclib\, phase 2.\nStudy: Dalpiciclib Plus AI (Neoadjuvant
  Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast
  Cancer （EBC）\nEstimated primary completion: 1 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/dalpiciclib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06107673
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04993430-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Dalpiciclib: Phase 1 readout est. (NCT04993430)
DESCRIPTION:Dalpiciclib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR639
 0 in Subjects With ER-Positive\, HER2-Negative Metastatic or Locally Advan
 ced Breast Cancer\nEstimated primary completion: 30 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/dalpiciclib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04993430
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06199271-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT06199271)
DESCRIPTION:Dalpiciclib\, phase 2.\nStudy: Neoadjuvant Adebrelimab Plus Dal
 piciclib in Head and Neck Squamous Cell Carcinoma\nEstimated primary compl
 etion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/dalpiciclib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06199271
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06556862-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT06556862)
DESCRIPTION:Dalpiciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Ca
 ncer After Failure of CDK4/6 Inhibitor\nEstimated primary completion: 31 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dalpici
 clib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06556862
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07238881-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07238881)
DESCRIPTION:Dalpiciclib\, phase 2.\nStudy: Dalpiciclib Plus Camrelizumab fo
 r HCC Patients Who Have Previously Received ICI Treatment\nEstimated prima
 ry completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/dalpiciclib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07238881
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06208410-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Dalpiciclib: Phase 1/2 readout est. (NCT06208410)
DESCRIPTION:Dalpiciclib\, phase 1/2.\nStudy: A Clinical Study of JS105 in C
 ombination With Other Anti-tumor Therapies in Patients With Solid Tumors\n
 Estimated primary completion: 26 February 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06208410
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06341894-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT06341894)
DESCRIPTION:Dalpiciclib\, phase 2.\nStudy: Efficacy and Safety of Dalpicicl
 ib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast
  Cancer\nEstimated primary completion: June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06341894
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778732-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07778732)
DESCRIPTION:Dalpiciclib\, phase 2.\nStudy: Adebrelimab Combined With Dalpic
 iclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally A
 dvanced Head and Neck Squamous Cell Carcinoma\nEstimated primary completio
 n: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dalpi
 ciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07778732
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06650748-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT06650748)
DESCRIPTION:Dalpiciclib\, phase 2.\nStudy: Multigene Risk Score Combined Wi
 th Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Tr
 eatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer\nEsti
 mated primary completion: 1 October 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06650748
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612814-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Dalpiciclib: Phase 3 readout est. (NCT06612814)
DESCRIPTION:Dalpiciclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ H
 ER2-Advanced Breast Cancer\nEstimated primary completion: 30 October 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/dalpiciclib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06612814
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06711094-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Dalpiciclib: Phase na readout est. (NCT06711094)
DESCRIPTION:Dalpiciclib\, phase na\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER
 2-ABC\nEstimated primary completion: 30 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06711094
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014410-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07014410)
DESCRIPTION:Dalpiciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-pos
 itive and HER2-positive Advanced Breast Cancer\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dalpiciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07014410
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285382-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07285382)
DESCRIPTION:Dalpiciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Different Doses of Dalpicicl Combined With Letrozole in the First-lin
 e Treatment of HR-positive\, HER2-negative Advanced Breast Cancer\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07285382
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Dalpiciclib\, phase 2.\nStudy: Fudan University Shanghai Cancer
  Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653451-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dalpiciclib: Phase 2/3 readout est. (NCT07653451)
DESCRIPTION:Dalpiciclib\, phase 2/3.\nStudy: Precision Medicine for Immunot
 herapy-Resistant Advanced Esophageal Cancer\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 lpiciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07653451
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05328440-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT05328440)
DESCRIPTION:Dalpiciclib\, phase 2.\nStudy: Treatment of Dalpiciclib Combine
 d With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DA
 P-Her-02)\nEstimated primary completion: 1 January 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05328440
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618923-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07618923)
DESCRIPTION:Dalpiciclib\, phase 2.\nStudy: Neoadjuvant Dalpiciclib + AI →
  SHR-A1811 for HR+/HER2-Low Breast Cancer\nEstimated primary completion: J
 une 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dalpiciclib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 18923
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07810088-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20280628
DTEND;VALUE=DATE:20280629
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07810088)
DESCRIPTION:Dalpiciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the 
 First-line Treatment for HR+/HER2- Advanced Breast Cancer\nEstimated prima
 ry completion: 28 June 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/dalpiciclib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07810088
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07706933-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Dalpiciclib: Phase na readout est. (NCT07706933)
DESCRIPTION:Dalpiciclib\, phase na.\nStudy: Tolerability of Dalpiciclib vs.
  Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer\nEstimated primar
 y completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/dalpiciclib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07706933
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652762-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Dalpiciclib: Phase 1 readout est. (NCT07652762)
DESCRIPTION:Dalpiciclib\, phase 1.\nStudy: IN10018 in Combination With Dalp
 iciclib for Progressive Meningiomas\nEstimated primary completion: August 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/dalpiciclib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0765276
 2
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07815522-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07815522)
DESCRIPTION:Dalpiciclib\, phase 2.\nStudy: Abiraterone With Dalpiciclib in 
 Salivary Gland Carcinoma\nEstimated primary completion: 1 October 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/dalpiciclib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07815522
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610720-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07610720)
DESCRIPTION:Dalpiciclib\, phase 2.\nStudy: Dalpiciclib\, Anti-HER2 Therapy\
 , and Endocrine Therapy for Hormone-Receptor-Positive\, HER2-Positive Meta
 static Breast Cancer\nEstimated primary completion: 1 November 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/dalpiciclib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07610720
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06099990-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dalpiciclib: Phase 1 readout est. (NCT06099990)
DESCRIPTION:Dalpiciclib\, phase 1.\nStudy: Dalpiciclib Isethionate Tablets 
 Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P
 ) Versus Placebo Combined With AA-P in Treatment of High-volume\, Metastat
 ic\, Hormone-sensitive Prostate Cancer (mHSPC)\nEstimated primary completi
 on: December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 lpiciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06099990
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07354022-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dalpiciclib: Phase 3 readout est. (NCT07354022)
DESCRIPTION:Dalpiciclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalp
 iciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to
  Adjuvant Endocrine Therapy.\nEstimated primary completion: December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/dalpiciclib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07354022
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07207070-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Dalpiciclib: Phase 3 readout est. (NCT07207070)
DESCRIPTION:Dalpiciclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Randomised\, Open-label\, Multicentre Phase III Clinical Study to E
 valuate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Ful
 vestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA
 -mutated\, HR-positive\, HER2-negative Recurrent or Metastatic Breast Canc
 er.\nEstimated primary completion: 31 May 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07207070
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07539753-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07539753)
DESCRIPTION:Dalpiciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in
  HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases\nE
 stimated primary completion: 1 August 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07539753
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06970912-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT06970912)
DESCRIPTION:Dalpiciclib\, phase 2.\nStudy: ctDNA-Guided De-Escalation of Ad
 juvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast C
 ancer\nEstimated primary completion: 31 December 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06970912
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07179939-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07179939)
DESCRIPTION:Dalpiciclib\, phase 2.\nStudy: Maintenance Therapy in HER2-Posi
 tive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase I
 I Study\nEstimated primary completion: 30 December 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07179939
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07892274-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Dalpiciclib: Phase 3 readout est. (NCT07892274)
DESCRIPTION:Dalpiciclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Trastuzumab Rezetecan Followed by Pyrotinib\, Fulvestrant\, and Dalpi
 ciclib in HR-Positive\, HER2-Positive Advanced Breast Cancer\nEstimated pr
 imary completion: 31 December 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07892274
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432178-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Dalpiciclib: Phase 3 readout est. (NCT07432178)
DESCRIPTION:Dalpiciclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small 
 Size High-risk ER-positive Breast Cancer（Cinnamon）\nEstimated primary 
 completion: 31 March 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/dalpiciclib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07432178
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101159-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07101159)
DESCRIPTION:Dalpiciclib\, phase 2.\nStudy: Dalpiciclib as Adjuvant Therapy 
 for HR-positive/HER2-negative Early-stage Patients\nEstimated primary comp
 letion: December 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dalpiciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07101159
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935226-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20311215
DTEND;VALUE=DATE:20311216
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07935226)
DESCRIPTION:Dalpiciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Induction Trastuzumab Rezetecan Followed by Maintenance Dalpiciclib a
 nd Endocrine Therapy as First-line Treatment of HR+/HER2 Low mBC\nEstimate
 d primary completion: 15 December 2031. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07935226
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581834-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Dalpiciclib: Phase 2 readout est. (NCT07581834)
DESCRIPTION:Dalpiciclib\, phase 2.\nStudy: Efficacy and Safety of Dalpicicl
 ib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Ca
 ncer: a Multicenter\, Prospective Clinical Study\nEstimated primary comple
 tion: 31 December 2031. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/dalpiciclib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07581834
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07467330-9053@assetmemo.bio
DTSTAMP:20261121T004449Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Dalpiciclib: Phase 3 readout est. (NCT07467330)
DESCRIPTION:Dalpiciclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabi
 ne vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment
 \nEstimated primary completion: 31 December 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dalpiciclib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07467330
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
